Compare CERS to:
After Hours: 0.00 N/A (N/A) 7:00pm ET
| Last Trade: | 1.90 |
|---|---|
| Trade Time: | Nov 27 |
| Change: | |
| Prev Close: | 1.95 |
| Open: | 1.90 |
| Bid: | 1.75 x 100 |
| Ask: | N/A |
| 1y Target Est: | 4.00 |
| Day's Range: | 1.87 - 1.91 |
|---|---|
| 52wk Range: | 0.55 - 3.57 |
| Volume: | 67,333 |
| Avg Vol (3m): | 715,420 |
| Market Cap: | 73.53M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.78 |
| Div & Yield: | N/A (N/A) |
| Fri, Nov 20 | Biotech Stock Mailbag: FDA Playbookat TheStreet.com |
| Wed, Nov 18 | Trading Review for Cerus Corp. Issued by Beacon EquityGlobeNewswire |
| Tue, Nov 17 | Biotech Stocks: Alkermes gains; Cerus, InterMune tumbleat MarketWatch |
| Tue, Nov 17 | CERUS CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online |
| Tue, Nov 17 | UPDATE - US panel suggests stricter trial safety margins: Cerusat Reuters |
| Tue, Nov 17 | Playboy, Helicos: Early Volume Playsat TheStreet.com |
| Tue, Nov 17 | Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial DesignBusiness Wire |
| Mon, Nov 16 | Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood SystemBusiness Wire |
| Fri, Nov 13 | CERUS CORP FinancialsEDGAR Online Financials |
| Fri, Nov 6 | CERUS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.